Oximio נותרה מחויבת לספק תרופות מצילות חיים למטופלים המעורבים בניסויים קליניים. אנו עוקבים באופן יזום אחר המצב המתפתח בישראל על-בסיס יומיומי, ככל שיתפתח. יתר על כן, אנו עובדים על פתרונות עבור לקוחות ומטופלים אשר עשויים להיות מושפעים מכל שיבוש בשרשרת האספקה על-מנת...
Oximio remains committed to delivering lifesaving drugs to patients involved in clinical trials. As the evolving situation in Israel continues, we are proactively monitoring the situation on a daily basis. Furthermore, we are working on solutions for clients and...
Following the submission of Oximio’s 2022 annual accounts, we reflect on the key takeaways which impacted the transformation of the company and its strategy. In the year which saw the beginning of the large-scale Russian invasion of Ukraine, the company’s finances...
Last week Oximio, Israel’s, Managing Director, Dror Sukenik and Pharmacist QP, Stanislav Liakhovski, were pleased to attend the Annual Conference for Clinical Studies in Israel. Held in Tel Aviv, there was a diverse program of events designed to keep those working...
1-3 November 2023 University of Pretoria, Hatfield, South Africa. Our Oximio teams in Africa and the UK will be heading to SACRA, in November. One of the country’s most highly anticipated conferences this year, supporting clinical trials within South Africa and Sub...
7 October, 2023. VDNG – Urban Park, Kyiv. This year, our Oximio family in Ukraine, will be joining forces with the Inspiration Family Cancer Foundation and running to help save and improve the quality of life for those fighting breast cancer. Did you know that each...
